3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase NA
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
22
Myelodysplastic Syndromes
18
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma
12
Leukemia
10
Multiple Myeloma
9
Hodgkin Disease
9
Neuroblastoma
8
Sarcoma
7
Lymphoma, Non-Hodgkin
6
Sarcoma, Ewing
5
Primary Myelofibrosis
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms, Plasma Cell
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Wilms Tumor
4
Rhabdomyosarcoma
4
Neuroectodermal Tumors, Primitive, Peripheral
4
Medulloblastoma
4
Lymphoma, Large B-Cell, Diffuse
4
Leukemia, Myelomonocytic, Chronic
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Hematologic Neoplasms
4
Graft vs Host Disease
4
Congenital Abnormalities
4
Central Nervous System Neoplasms
4
Astrocytoma
4
Testicular Neoplasms
3
Retinoblastoma
3
Optic Nerve Glioma
3
Interventions
venetoclax
6
Azacitidine
6
Cytarabine
5
fludarabine
4
Methotrexate
3
fludarabine phosphate
2
aldesleukin
2
RO6839921
2
Mitoxantrone
2
Interleukin-2
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Decitabine
2
Dasatinib
2
zileuton
1
thymoglobulin
1
spartalizumab
1
sabatolimab
1
quizartinib
1
pulrodemstat besilate
1
posaconazole
1
plerixafor
1
gilteritinib
1
etoposide phosphate
1
emvododstat
1
daratumumab
1
blinatumomab
1
Sorafenib
1
Sirolimus
1
Panobinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myeloid
×
Busulfan
×
Clear all
NCT02916979
2023-10-18
FluBuATG
Dartmouth-Hitchcock Medical Center
Phase 1
Completed
20 enrolled